Silent coeliac disease is over‐represented in children with type 1 diabetes and their siblings

By  

ACTA PAEDIATRICA, Vol. 104, Iss. 2, 2015-02 ,pp. : 185-191

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of a risk‐based secondary screening programme of type 2 diabetes

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 32, Iss. 7, 2016-10 ,pp. : 710-729

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis*

By Tunis Sandra L.   Minshall Michael E.   Conner Christopher   McCormick John I.   Kapor Jovana   Yale Jean-François   Groleau Danielle  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1273-1284

Informa Healthcare

Access to resources Recommend Favorite

The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Cost-effectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making

By Palmer Andrew J.   Roze Stéphane   Valentine William J.   Minshall Michael E.   Foos Volker   Lurati Francesco M.   Lammert Morten   Spinas Giatgen A.  

Current Medical Research and Opinion, Vol. 20, Iss. 1, 2004-08 ,pp. : 5-26

Informa Healthcare

Access to resources Recommend Favorite

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 890-898

John Wiley & Sons Inc

Access to resources Recommend Favorite